MeSH D020246 - venous thrombosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| LEO Pharma | Tinzaparin | Innohep |  | 2000-07-14 |  |  |
| Mylan | Apixaban | Apixaban |  | 2019-12-23 |  |  |
| Fondaparinux | Arixtra |  | 2001-12-07 |  |  | |
| Rivaroxaban | Rivaroxaban Viatris (previously Rivaroxaban Mylan) |  | 2021-11-12 |  |  | |
| Johnson & Johnson | Rivaroxaban | Xarelto | 2024-08-28 | 2011-07-01 | $2,305 M | Q2/23-Q1/24 |
| GSK | Fondaparinux | Quixidar |  | 2002-03-21 |  |  |
| Organon | Phenprocoumon | Liquamar |  | 1982-01-01 |  |  |
| Bayer | Rivaroxaban | Xarelto |  | 2008-09-30 |  |  |
| Dr Reddys Laboratories | Fondaparinux | Fondaparinux |  | 2011-07-11 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
79%11/14
Phase 2
91%20/22
Phase 3
78%35/45
Approved: 14Overall Success rate: 56%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use